In The News

The Big Biz Show – Interview with Dr. Elliot Goldstein

European Biopharmaceutical Review July 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Ending Parkinson’s disease: The path is getting shorter

Alzheimer’s Disease is a ‘Double-Prion Disorder,’ Study Shows

Guest Commentary: Targeting α-synuclein and the pathogenesis of Parkinson’s disease

Attacking the Right Therapeutic Target in Alzheimer’s Disease

Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

ProMIS tackles Parkinson's and Alzheimer’s diseases

ProMIS Neurosciences (TSX:PMN): Targeting the root cause of Alzheimer’s and other neurodegenerative diseases